Export 21 results:
Autore Titolo [ Tipo(Asc)] Anno
Filtri: Autore è Piscianz, Elisa  [Clear All Filters]
Journal Article
Marcuzzi A, Piscianz E, Zweyer M, Bortul R, Loganes C, Girardelli M, Baj G, Monasta L, Celeghini C. Geranylgeraniol and Neurological Impairment: Involvement of Apoptosis and Mitochondrial Morphology. Int J Mol Sci 2016;17(3):365.
Taddio A, Biondi A, Piscianz E, Valencic E, Biagi E, Badolato R. From bone marrow transplantation to cellular therapies: possible therapeutic strategies in managing autoimmune disorders. Curr Pharm Des 2012;18(35):5776-81.
Piscianz E, Valencic E, Cuzzoni E, De Iudicibus S, De Lorenzo E, Decorti G, Tommasini A. Fate of lymphocytes after withdrawal of tofacitinib treatment. PLoS One 2014;9(1):e85463.
Zanin V, Marcuzzi A, Piscianz E, Vuch J, Bianco AMonica, Monasta L, Decorti G, Crovella S. The effect of clodronate on a mevalonate kinase deficiency cellular model. Inflamm Res 2012;61(12):1363-7.
Piscianz E, Cuzzoni E, De Iudicibus S, Valencic E, Decorti G, Tommasini A. Differential action of 3-hydroxyanthranilic acid on viability and activation of stimulated lymphocytes. Int Immunopharmacol 2011;11(12):2242-5.
Loganes C, Lega S, Bramuzzo M, Brumatti LVecchi, Piscianz E, Valencic E, Tommasini A, Marcuzzi A. Curcumin Anti-Apoptotic Action in a Model of Intestinal Epithelial Inflammatory Damage. Nutrients 2017;9(6)
Bernardi S, Marcuzzi A, Piscianz E, Tommasini A, Fabris B. The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases. Int J Mol Sci 2018;19(12)
Lougaris V, Faletra F, Lanzi G, Vozzi D, Marcuzzi A, Valencic E, Piscianz E, Bianco AM, Girardelli M, Baronio M, Loganes C, Fasth A, Salvini F, Trizzino A, Moratto D, Facchetti F, Giliani S, Plebani A, Tommasini A. Altered germinal center reaction and abnormal B cell peripheral maturation in PI3KR1-mutated patients presenting with HIGM-like phenotype. Clin Immunol 2015;159(1):33-6.
Piscianz E, Candilera V, Valencic E, Loganes C, Paron G, De Iudicibus S, Decorti G, Tommasini A. Action of methotrexate and tofacitinib on directly stimulated and bystander-activated lymphocytes. Mol Med Rep 2016;14(1):574-82.

Amministrazione Trasparente